On January 6, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square (Press release, Phio Pharmaceuticals, JAN 6, 2020, View Source [SID1234552706]). Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation at Biotech Showcase, Dr. Dispersyn will discuss Phio’s proprietary gene-silencing technology INTASYLTM and provide updates on its broad early-stage pipeline applying INTASYL both as a standalone therapy and in combination with adoptive cell-therapy. This will include updates on the Company’s lead product candidates PH-762, designed to silence PD-1 receptor expression on T cells, and PH-804, designed to silence expression of TIGIT on T cells and NK cells.

Details of the presentation are as follows:

Date:

Monday, January 13, 2020

Time:

2:00 p.m. (PST)

Track:

Yosemite C (Ballroom Level)

Location:

Hilton San Francisco Union Square

A live audio webcast of the presentation will be made available on the Events section of the Company’s website at View Source with a replay accessible following the live presentation.